COMMUNIQUÉS West-GlobeNewswire

MedWell Ai, Inc Reports Q3 Revenues Of $618,676 And Provides Corporate Update
06/05/2026
CLEARWATER, Fla., May 06, 2026 (GLOBE NEWSWIRE) -- via IBN -- MedWell Ai, Inc, (OTCQB:MWAI) ("Company") is a portfolio company, specializing in AI-driven solutions for B2B markets in pharmaceuticals, healthcare, and [...]
Cannara complète l’acquisition de Medican Organic Inc.
06/05/2026
MONTRÉAL, 06 mai 2026 (GLOBE NEWSWIRE) -- Cannara Biotech Inc. (« Cannara », « la Société », « nous ») ( TSX : LOVE ) ( OTCQX : LOVFF ) ( FRA : 8CB0 ), producteur verticalement intégré de cannabis de qualité supérieure [...]
CRISPR Therapeutics to Present at the Bank of America Securities 2026 Global Healthcare Conference
06/05/2026
ZUG, Switzerland and BOSTON, May 06, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today announced that members of its senior management team will present at the Bank of America Securities 2026 Global [...]
Bioxodes presents positive final Phase 2a intracerebral hemorrhage results at ESOC affirming breakthrough potential of BIOX-101
06/05/2026
Final results confirm and build on interim BIRCH results in 23 ICH patients Primary safety endpoint met with no mortality observed Encouraging efficacy signals on all clinical and biomarker endpoints New adaptive [...]
Rhythm Pharmaceuticals Announces Participation in Upcoming Bank of America Global Healthcare Conference
06/05/2026
BOSTON, May 06, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine [...]
InflaRx Announces Pricing of $150 Million Underwritten Offering of Ordinary Shares
06/05/2026
Jena, Germany, May 06, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX) (the “Company”), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, announced today the [...]
Milestone Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 13, 2026
06/05/2026
MONTREAL and CHARLOTTE, May 06, 2026 (GLOBE NEWSWIRE) -- Milestone ® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular [...]
SeaStar Medical to Report First Quarter Financial Results on May 13, 2026
06/05/2026
DENVER, May 06, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and [...]
Pathos AI Acquires Majority Stake in DeuterOncology to Advance Next-Generation MET Inhibitor Identified by Pathos Foundry Platform
06/05/2026
Transaction marks one of the first clinical-stage oncology acquisitions sourced, evaluated, and executed through an AI-powered drug development platform NEW YORK, May 06, 2026 (GLOBE NEWSWIRE) -- Pathos AI, a clinical- [...]
Shareholders vote in favor of all proposals by the Board at Idorsia’s Annual General Meeting 2026
06/05/2026
Allschwil, Switzerland – May 6, 2026 At today’s Annual General Meeting (AGM) of Idorsia Ltd (SIX: IDIA) held in Basel, Switzerland, shareholders voted convincingly in favor of all proposals by the Board of Directors. [...]
Where Executives Are Doubling Down on Their Companies’ Fortunes
06/05/2026
4 Stocks Under $15 Seeing Aggressive Insider Buying Activity DENVER, May 06, 2026 (GLOBE NEWSWIRE) -- 24/7 Market News and NeOnc Technology -- As market participants are sifting through data, one signal often cuts [...]
Better Blend Continues Growth with Second Lexington Location
06/05/2026
Fast-growing Midwest brand brings low-sugar, high-protein menu to the area LEXINGTON, Ky., May 06, 2026 (GLOBE NEWSWIRE) -- Better Blend, a rapidly growing smoothie and bowl brand, opened its second location in [...]
Annexon to Present at the Bank of America Securities Health Care Conference 2026
06/05/2026
BRISBANE, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that [...]
Becoming Independent Celebrates Outstanding Individuals and Partners at Second Annual Spotlight Awards
06/05/2026
Charles M. Schulz Museum, Morton & Bassett Spices, Alsco Uniforms among those honored SANTA ROSA, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- Becoming Independent , a nonprofit supporting adults with disabilities live [...]
Allogene Therapeutics to Report First Quarter Financial Results and Provide Business Update
06/05/2026
Conference Call and Webcast Scheduled for May 13, 2026 at 2 p.m. PT/5 p.m. ET SOUTH SAN FRANCISCO, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology [...]
Orchestra BioMed Receives $15 Million Investment from Ligand Under Previously Announced Strategic Financing Agreement
06/05/2026
$15 million payment fulfills previously scheduled tranche under royalty-based financing agreement, bringing total capital received from Ligand to $40 million to date in exchange for tiered royalty interest in Orchestra [...]
NEXGEL Appoints Brian Kieser and Kevin Harris from New Strategic Partner, Sequence LifeScience™, to Board of Directors
06/05/2026
Sequence LifeScience TM Led Financing to Close on Acquisition of Celularity with Strategic Investment of $5.5 Million LANGHORNE, Pa., May 06, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “ [...]
Jito Foundation and Solana Company (NASDAQ: HSDT) Announce Strategic Partnership to Expand Institutional Solana Infrastructure Across Asia-Pacific Region
06/05/2026
Pairing Jito's market layer technology and Solana Company's institutional Pacific Backbone platform intended to advance validator infrastructure and staking solutions across Asia-Pacific MIAMI, May 06, 2026 (GLOBE [...]
SCIENTURE Announces Third Patent Grant for ARBLI™ (losartan potassium) Oral Suspension, Strengthening Long-Term Market Exclusivity Through 2041
06/05/2026
U.S. losartan market totals approximately $241M annually with around 72M prescriptions, creating a significant opportunity for ARBLI ™ as the first FDA-approved ready-to-use oral suspension COMMACK, NY, May 06, 2026 ( [...]

Pages